» Articles » PMID: 33727100

Temporal Profile and Utility of Serum Neurofilament Light in a Rat Model of Mild Traumatic Brain Injury

Overview
Journal Exp Neurol
Specialty Neurology
Date 2021 Mar 17
PMID 33727100
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

There is a widely recognized need for blood biomarkers to assist clinical decisions surrounding mild traumatic brain injury (mTBI). Serum neurofilament light (NfL), an indicator of neuroaxonal damage, is one such candidate, with early mTBI clinical investigations demonstrating significant promise. To facilitate the translation of pre-clinical mTBI findings, clinically relevant outcomes should be integrated into animal studies wherever possible. Despite this, the temporal profile and potential utility of NfL as a blood biomarker in pre-clinical mTBI is poorly understood. Here, we quantified serum NfL at 2-h, 1-, 3-, 7- and 14-days following mTBI in rats and compared these to pre-injury levels. We also investigated cumulative effects of repeat-mTBI by delivering 0, 1 or 5 mTBIs separated by 24 h. Sensorimotor performance was evaluated with the beam task at 1- and 4-h after mTBI, and serum was collected 1-day after the final procedure. We found that serum NfL levels were substantially elevated at all acute and sub-acute time-points after a single-mTBI, peaked at 1-day, and remained elevated 14-days post-injury. An mTBI dose-dependent effect on serum NfL levels was also observed, with substantially higher NfL levels found at 1-day post repeat-mTBI when compared to single-mTBI and sham-injured rats. Furthermore, NfL levels were found to be greatest in rats with the highest degree of sensorimotor impairment. In conclusion, these findings have described the temporal profile of serum NfL elevations following a single-mTBI in rats, and indicate a profile with some similarities and differences to that seen in the clinical condition. Moreover, we found that serum NfL levels were potentiated by repeat-mTBI, and that this biomarker may have utility as an indicator of injury severity. As such, future pre-clinical TBI studies may benefit from incorporating measures of serum NfL as an objective injury outcome.

Citing Articles

Investigating the role of the brain-derived neurotrophic factor Val66Met polymorphism in repetitive mild traumatic brain injury outcomes in rats.

Giesler L, OBrien W, Bain J, Spitz G, Jaehne E, van den Buuse M Behav Brain Funct. 2025; 21(1):5.

PMID: 40045366 PMC: 11884142. DOI: 10.1186/s12993-025-00270-5.


Cortical spheroids show strain-dependent cell viability loss and neurite disruption following sustained compression injury.

Gonzalez-Cruz R, Wan Y, Burgess A, Calvao D, Renken W, Vecchio F PLoS One. 2024; 19(8):e0295086.

PMID: 39159236 PMC: 11332998. DOI: 10.1371/journal.pone.0295086.


Advances in development of biomarkers for brain damage and ischemia.

Karimova D, Rostami E, Chubarev V, Tarasov V, Schioth H, Rask-Andersen M Mol Biol Rep. 2024; 51(1):803.

PMID: 39001884 PMC: 11246271. DOI: 10.1007/s11033-024-09708-x.


Temporal Profile of Serum Neurofilament Light (NF-L) and Heavy (pNF-H) Level Associations With 6-Month Cognitive Performance in Patients With Moderate-Severe Traumatic Brain Injury.

Trifilio E, Bottari S, McQuillan L, Barton D, Lamb D, Robertson C J Head Trauma Rehabil. 2024; 39(6):E470-E480.

PMID: 38758056 PMC: 11534502. DOI: 10.1097/HTR.0000000000000932.


Performance of biomarkers NF-L, NSE, Tau and GFAP in blood and cerebrospinal fluid in rat for the detection of nervous system injury.

Vlasakova K, Tsuchiya T, Garfinkel I, Ruth M, Tyszkiewicz C, Detwiler T Front Neurosci. 2024; 17:1285359.

PMID: 38292901 PMC: 10824906. DOI: 10.3389/fnins.2023.1285359.